Ohio Medicaid covers GLP-1 medications only for specific diagnoses. The program pays for drugs like Ozempic and Mounjaro when they are prescribed for Type 2 diabetes, and starting April 1, 2026, it covers Wegovy for two narrow uses: reducing cardiovascular risk in certain high-risk patients and treating a liver condition called MASH. Ohio Medicaid does not cover any GLP-1 prescribed solely for weight loss.
What’s Covered and What’s Excluded
Ohio Medicaid’s pharmacy benefit draws a firm line. The state’s pharmacy benefit manager site states that “for all other non-FDA approved uses (such as prediabetes or weight loss), coverage will not be available.”1Ohio Medicaid SPBM Portal. Ohio Medicaid Single Pharmacy Benefit Manager The exclusion applies whether you are enrolled through a managed care plan like Molina, CareSource, or UnitedHealthcare, or through fee-for-service. The official member pharmacy handbook confirms that the program does not cover “drugs for the treatment of obesity.”2Ohio Medicaid. SPBM Member Handbook
The distinction often comes down to which brand and indication your prescriber writes for. Wegovy and Zepbound, marketed for obesity, are excluded when prescribed for that purpose. The same active ingredients packaged for diabetes, Ozempic (semaglutide) and Mounjaro (tirzepatide), can be covered when the prescription is tied to a Type 2 diabetes diagnosis and cleared through prior authorization.
Coverage for Type 2 Diabetes
If you have Type 2 diabetes, several GLP-1s sit on Ohio Medicaid’s preferred drug list. The current preferred agents are Byetta (exenatide), Trulicity (dulaglutide), and Victoza (liraglutide). These generally do not require prior authorization beyond a documented diabetes diagnosis.1Ohio Medicaid SPBM Portal. Ohio Medicaid Single Pharmacy Benefit Manager
Ozempic and Mounjaro are handled differently. Since September 2024, both require prior authorization if you do not already have an active authorization on file, and the request is reviewed against the clinical criteria on the Unified Preferred Drug List. As of December 8, 2025, every claim for a preferred GLP-1 must also include a documented Type 2 diabetes diagnosis, either in the medical record or on the pharmacy claim itself.1Ohio Medicaid SPBM Portal. Ohio Medicaid Single Pharmacy Benefit Manager
Coverage for Cardiovascular Risk and MASH Starting April 2026
Ohio Medicaid’s Pharmacy and Therapeutics Committee created a new drug category called “Metabolic Modifiers” and approved Wegovy as the preferred agent for two non-diabetes uses, effective April 1, 2026: reducing the risk of major adverse cardiovascular events (MACE), and treating metabolic dysfunction-associated steatohepatitis (MASH).3Ohio Department of Medicaid. 30-Day Change Notice, Effective April 1, 2026 Both indications require clinical prior authorization, and the criteria are strict.
Cardiovascular Risk Reduction (MACE)
To qualify, you must be 18 or older, have a BMI of at least 27, and must not have Type 1 or Type 2 diabetes (A1C below 6.5%). You need a documented history of a prior heart attack, stroke, or symptomatic peripheral artery disease. You also must already be receiving standard cardiovascular treatment: an antiplatelet agent, a lipid-lowering drug, and blood pressure medication.3Ohio Department of Medicaid. 30-Day Change Notice, Effective April 1, 2026
MASH
To qualify, you must be 18 or older with documented noncirrhotic MASH and moderate to advanced liver fibrosis (stage F2 or F3). Confirmation requires a liver biopsy within the past 24 months or a combination of two qualifying diagnostic tests. You must also be following a reduced-calorie diet and exercise plan and have optimized treatment for related conditions such as coronary artery disease and high cholesterol.4Ohio Department of Medicaid. Pharmacy and Therapeutics Committee Meeting Minutes, January 7, 2026
Renewals
Both authorizations last 180 days. For renewal, you must show at least 5% weight loss from baseline and 80% adherence to the medication. MASH renewals additionally require measurable improvement in liver inflammation or fibrosis.3Ohio Department of Medicaid. 30-Day Change Notice, Effective April 1, 2026
How To Get Prior Authorization
All Ohio Medicaid pharmacy prior authorization requests go through Gainwell, the state’s single pharmacy benefit manager. Your prescribing provider is responsible for submitting the request. Providers can file electronically through the Agadia PromptPA Portal, by fax at 833-679-5491, or by phone at 833-491-0344. Forms are on the SPBM portal, and requests are processed within 24 hours.1Ohio Medicaid SPBM Portal. Ohio Medicaid Single Pharmacy Benefit Manager
How To Appeal a Denial
If your prior authorization is denied, you have 60 calendar days from the date on the denial letter to file an appeal. You can appeal by phone (1-833-491-0344, option 1), by email to OH_MCD_PBM@gainwelltechnologies.com, through the SPBM member portal, or by mail to Gainwell Pharmacy Services. Include your name, Medicaid ID, the prescriber’s name, and why you disagree with the denial. Gainwell must respond within 15 calendar days, and expedited review is available if the standard timeline would jeopardize your health.5Ohio Medicaid. Member Pharmacy FAQs
If the appeal is also denied, you can request a state hearing within 90 calendar days of the appeal decision. State hearing requests can be filed online at the Ohio Department of Job and Family Services portal, by phone at 1-866-635-3748, or by email to bsh@jfs.ohio.gov.5Ohio Medicaid. Member Pharmacy FAQs
Why Weight Loss Is Excluded
Federal Medicaid law generally requires states to cover nearly all FDA-approved drugs from participating manufacturers, but 42 U.S.C. ยง 1396r-8 carves out an exception for drugs “used for anorexia, weight loss, or weight gain.”6KFF. Medicaid Coverage of and Spending on GLP-1s That makes obesity coverage optional for states. Coverage for other FDA-approved uses, including diabetes and cardiovascular risk reduction, is mandatory.
The spending numbers help explain Ohio’s choice. GLP-1 spending in Ohio Medicaid rose from $172 million serving 30,000 recipients in fiscal year 2021 to nearly $431 million serving 75,000 recipients in the most recent fiscal year reported.7CW Columbus. Ohio GLP-1 Drug Coverage Costs Nationally, gross Medicaid spending on GLP-1s climbed from roughly $1 billion in 2019 to nearly $9 billion in 2024. Ohio is in the majority of states that do not cover GLP-1s for obesity; as of January 2026, only 13 state Medicaid programs did so.6KFF. Medicaid Coverage of and Spending on GLP-1s
What Could Change
Two federal actions could eventually broaden coverage. The BALANCE model, launched by the Trump administration in December 2025 through the CMS Innovation Center, is a voluntary five-year demonstration in which manufacturers negotiate lower GLP-1 prices for participating state Medicaid programs and Medicare. Medicaid coverage expansion under the model began May 1, 2026, with a state application deadline of July 31, 2026, and the model runs through December 2031.8KFF. What to Know About the BALANCE Model for GLP-1s in Medicare and Medicaid Whether Ohio will participate is not yet known.
Separately, CMS proposed a rule (CMS-4208-P) that would require state Medicaid programs to cover anti-obesity medications, overriding the federal exclusion. The National Association of Medicaid Directors has objected to the proposed 60-day implementation timeline as unrealistic and projected annual costs of $30 million to $126 million per state depending on size.9National Association of Medicaid Directors. Optional, Not Mandatory: NAMDs Recommendations on Anti-Obesity Medication Coverage Congress has also reintroduced the Treat and Reduce Obesity Act in both chambers of the 119th Congress, which would remove the statutory weight-loss drug exclusion from Medicaid.10U.S. Congress. H.R. 4231, Treat and Reduce Obesity Act of 2025 Neither the CMS rule nor the legislation has been finalized, and no pending Ohio bill would expand Medicaid coverage of GLP-1s for obesity.